双氯芬酸钠与塞来昔布治疗类风湿关节炎的疗效及对心血管的影响研究

The Clinical Effect of Diclofenac and Celecoxib in Treatment of Rheumatoid Arthritis and its Effect on the Cardiovascular

目的:探讨双氯芬酸钠和塞来昔布治疗类风湿关节炎的临床疗效及用药安全性。方法:将我院2011年1月-2012年1月门诊收治的98例类风湿性关节炎患者随机分为对照组和观察组,每组49例。对照组给予双氯芬酸钠治疗,观察组给予塞来昔布治疗,观察两组临床治疗效果及心血管不良事件的发生情况。结果:观察组总有效率为91.84%显著高于对照组的75.51%,两组比较差异具有统计学意义(P<0.05);观察组ESR及CRP分别为(110.65±7.28)mm/h和(10.42±0.98)mg/L显著低于治疗前和对照组,比较差异具有统计学意义(P<0.05);观察组心血管不良事件发生率为8.16%显著低于对照组的20.41%,两组比较差异具有统计学意义(P<0.05)。结论:塞来昔布治疗类风湿关节炎具有较好的临床疗效,可有效改善患者疼痛、僵硬或功能受限等症状,且心血管不良事件发生率低,值得临床进一步推广和应用。

Objective： To investigate the clinical efficacy and medication safety of diclofenac and celecoxib in the treatment of rheumatoid arthritis. Methods： 98 patients with the rheumatoid who were treated in our hospital from January 2011 to 2012 were selected and randomly divided into the control group and the observation group with 49 cases in each one. The patients in the control group were treated by the diclofenac, while the patients in the observation group were treated by the celecoxib. Then the clinical effect and the occur- rence of adverse cardiovascular were observed and compared between two groups two groups. Results： In the observation group, the total effective rate in the observation group was 91.84%, the ESR was （110.65~ 7.28） mm/h and the CRP was （10.42＋ 0.98） mg/L which were significantly different when comparing with the control group（P〈0.05）; the incidence of adverse cardiovascular events of patients in the observation group was 8.16% which was significantly lower than 20.41% in the control group （P〈0.05）. Conclusion： It is indicated that the effects of Celecoxib on the treatment of rheumatoid arthritis should be worthy to be promoted to the clinical with the advantages of better efficacy, and low incidence of adverse cardiovascular reactions.